These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11091277)

  • 21. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
    Ribeiro PAF; Dias DS; Lage DP; Costa LE; Martins VT; Tavares GSV; Mendonça DVC; Lima MP; Oliveira JS; Steiner BT; Machado-de-Ávila RA; Roatt BM; Chávez-Fumagalli MA; Menezes-Souza D; Duarte MC; Teixeira AL; Coelho EAF
    Cell Immunol; 2018 Sep; 331():67-77. PubMed ID: 29871740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
    Ghosh A; Zhang WW; Matlashewski G
    Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge.
    Chávez-Fumagalli MA; Costa MA; Oliveira DM; Ramírez L; Costa LE; Duarte MC; Martins VT; Oliveira JS; Olortegi CC; Bonay P; Alonso C; Tavares CA; Soto M; Coelho EA
    Microbes Infect; 2010 Nov; 12(12-13):967-77. PubMed ID: 20601076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis.
    Soto M; Requena JM; Quijada L; Guzman F; Patarroyo ME; Alonso C
    Immunol Lett; 1995 Nov; 48(1):23-8. PubMed ID: 8847086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral Leishmaniasis.
    Martins VT; Chávez-Fumagalli MA; Lage DP; Duarte MC; Garde E; Costa LE; da Silva VG; Oliveira JS; Magalhães-Soares DF; Teixeira SM; Fernandes AP; Soto M; Tavares CA; Coelho EA
    PLoS One; 2015; 10(9):e0137683. PubMed ID: 26367128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83.
    Rico AI; Angel SO; Alonso C; Requena JM
    Mol Immunol; 1999 Dec; 36(17):1131-9. PubMed ID: 10698315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic properties of a Leishmania-specific hypothetical protein in a murine model of visceral leishmaniasis.
    Lage DP; Martins VT; Duarte MC; Garde E; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Parasite Immunol; 2015 Dec; 37(12):646-56. PubMed ID: 26457798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. During canine viscero-cutaneous leishmaniasis the anti-Hsp70 antibodies are specifically elicited by the parasite protein.
    Quijada L; Requena JM; Soto M; Alonso C
    Parasitology; 1996 Mar; 112 ( Pt 3)():277-84. PubMed ID: 8728991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
    Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
    Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection.
    Ribeiro PAF; Dias DS; Lage DP; Martins VT; Costa LE; Santos TTO; Ramos FF; Tavares GSV; Mendonça DVC; Ludolf F; Gomes DA; Rodrigues MA; Chávez-Fumagalli MA; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Mol Immunol; 2019 Feb; 106():108-118. PubMed ID: 30594673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leishmania cytosolic silent information regulatory protein 2 deacetylase induces murine B-cell differentiation and in vivo production of specific antibodies.
    Silvestre R; Cordeiro-da-Silva A; Tavares J; Sereno D; Ouaissi A
    Immunology; 2006 Dec; 119(4):529-40. PubMed ID: 17026719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new Leishmania-specific hypothetical protein, LiHyT, used as a vaccine antigen against visceral leishmaniasis.
    Martins VT; Lage DP; Duarte MC; Costa LE; Garde E; Rodrigues MR; Chávez-Fumagalli MA; Menezes-Souza D; Roatt BM; Tavares CA; Soto M; Coelho EA
    Acta Trop; 2016 Feb; 154():73-81. PubMed ID: 26593442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.